Pfizer Acquires Weight-Loss Biotech to Strengthen Pipeline in Growing Market
Pfizer has acquired Metsera for $7 billion, gaining access to promising weight-loss drug MET-097i. The GLP-1 medication showed a mean placebo-subtracted weight loss of up to 14.1% after 28 weeks and is in phase 3 trials. With the global weight management market projected to exceed $100 billion by the next decade, Pfizer aims to position itself as a leader.
Topics: GLP-1 medications Metsera acquisition Pfizer weight management drugs